Gene editing is already available as an approved medical treatment, but only for a handful of conditions. The first CRISPR-based therapy, Casgevy, was authorized in the UK in November 2023 and approved by the FDA in December 2023 for sickle cell disease. Several more gene editing treatments are expected to reach the market between 2027 and 2030, with dozens of clinical trials underway for conditions ranging from hereditary heart disease to inherited blindness.
The short answer: if you have sickle cell disease, gene editing is available now. For most other conditions, you’re likely looking at a three-to-ten-year wait, depending on how trials progress and how quickly regulators move.
What’s Already Approved
On December 8, 2023, the FDA approved two gene therapies for sickle cell disease in patients 12 and older: Casgevy (made by Vertex Pharmaceuticals) and Lyfgenia (made by Bluebird Bio). Casgevy is the one that uses CRISPR genome editing. Lyfgenia uses a different gene therapy approach. The UK’s medicines regulator actually beat the FDA by a few weeks, authorizing Casgevy in November 2023 for both sickle cell disease and a related blood disorder called beta-thalassemia.
The treatment works by removing stem cells from a patient’s bone marrow, editing them in a lab to restore healthy hemoglobin production, and infusing them back. In trials, the majority of participants saw their symptoms resolve. It’s a one-time treatment, but it’s intensive. Patients typically need to spend at least a month in a hospital while the modified cells establish themselves in the bone marrow.
Treatments Expected by 2027 to 2030
The most advanced pipeline involves a condition called hereditary transthyretin amyloidosis, a disease where a misfolded protein gradually damages the heart and nerves. Intellia Therapeutics is running two separate phase III trials for this condition, one focused on patients with heart damage and one on nerve damage. They began dosing participants in spring 2024 and have publicly stated they hope to have the treatment commercially available by 2027.
What makes this trial particularly significant is that it’s an “in vivo” treatment, meaning the gene editing components are delivered directly into the body through an IV infusion rather than editing cells in a lab dish first. The CRISPR system is packaged inside tiny fat-based particles called lipid nanoparticles that travel to the liver and edit cells there. If this approach succeeds at scale, it would open the door to treating a much wider range of diseases without the complex process of extracting and reimplanting cells.
Intellia is also running a phase III trial for hereditary angioedema, a condition that causes severe, unpredictable swelling episodes. They dosed the first participant in January 2025 and are enrolling 40 people at the higher dose level.
Vision and Cancer
For inherited blindness, a CRISPR treatment called EDIT-101 completed a clinical trial for Leber congenital amaurosis type 10, a rare genetic condition that severely impairs vision from birth. Results published in the New England Journal of Medicine showed that about 79% of the 14 participants experienced measurable vision improvement after receiving the treatment in one eye. This was the first time CRISPR was used to edit genes directly inside a person’s body (in this case, injected into the eye). No FDA-approved treatment exists yet for this condition, but the trial results are promising enough to expect further development.
In cancer, researchers are using CRISPR to enhance a well-established approach called CAR-T therapy, where a patient’s immune cells are engineered to attack tumors. Several CAR-T products are already FDA-approved for blood cancers, and CRISPR is being used to make next-generation versions that are more effective or can be manufactured from donor cells rather than requiring each patient’s own. These are still working through clinical trials.
Why Most Conditions Are Still Years Away
The biggest bottleneck isn’t the editing itself. CRISPR can reliably cut and modify DNA in a lab. The challenge is getting the editing tools to the right cells inside a living person without causing harm elsewhere.
Current delivery methods each have limitations. Viral vectors (harmless viruses repurposed to carry CRISPR components) can target specific organs like the liver, lungs, or brain, but they can trigger immune reactions and can only carry a limited amount of genetic material. Lipid nanoparticles work well for reaching the liver but are harder to direct to other tissues. Gold nanoparticles show promise in lab settings but raise concerns about toxicity. Every delivery system also carries the risk that CRISPR edits genes it wasn’t supposed to, known as off-target effects.
Off-target editing is the safety concern that regulators take most seriously. In a test tube, an unintended edit might be a minor data point. Inside a person, it could theoretically disrupt a tumor-suppressing gene or cause other unpredictable problems. The risk is especially high with in vivo treatments, where the editing tools circulate through the body rather than being applied to isolated cells in a controlled lab environment. Another complication: if the CRISPR machinery stays active too long after injection, it increases the window for both immune reactions and off-target cuts. Research from gene therapy trials shows that genetic material delivered by viral vectors can remain active for up to 10 years, which is a double-edged sword.
These challenges explain why the liver is the first organ being targeted for in vivo CRISPR treatments. Lipid nanoparticles naturally accumulate there, making delivery relatively straightforward. Reaching the brain, lungs, muscles, or kidneys with the same precision is a harder problem that will take longer to solve.
Cost and Access
Even where gene editing is approved, access is limited by price. Both Casgevy and Lyfgenia carry list prices above $2 million per treatment. Medicare approved add-on payments for both therapies in fiscal year 2025, covering up to $2.325 million for Lyfgenia and $1.65 million for Casgevy. Medicaid also covers these treatments, though individual states can set their own eligibility limits, and rebate agreements bring the actual cost below the list price.
Private insurance is a more complicated picture. The five largest U.S. health insurance companies have established coverage for these gene therapies, but their criteria are more restrictive than what the FDA approved. In practice, this means some patients who are medically eligible may still face barriers getting their insurer to pay.
The cost question will shape how quickly gene editing expands beyond rare diseases. A $2 million one-time treatment can make economic sense for a severe, lifelong condition like sickle cell disease, where the alternative is decades of hospitalizations, blood transfusions, and pain management. For more common conditions, the math changes. Treatments for high cholesterol or heart disease, which are in early development, would need to be dramatically cheaper to reach a broad population.
A Realistic Timeline
Here’s a rough picture of what to expect over the next several years. By 2027, one or two additional CRISPR therapies are likely to reach the market, most probably for hereditary transthyretin amyloidosis. Between 2028 and 2032, expect approvals to accelerate as delivery technology improves and regulatory agencies develop more streamlined pathways for reviewing gene editing treatments. Conditions affecting the liver will come first because the delivery problem is largely solved for that organ.
Diseases affecting the brain, muscles, or multiple organ systems are further out. The technology to safely and efficiently deliver gene editing tools to those tissues is still being refined in labs and early-phase trials. For common, complex conditions like heart disease, diabetes, or Alzheimer’s, gene editing as a routine clinical option is likely a decade or more away, if it proves feasible at all. These conditions typically involve many genes interacting with lifestyle and environmental factors, which is a fundamentally harder problem than fixing a single known mutation.
The pace of progress has been faster than most scientists predicted even five years ago. The first human CRISPR trial began in 2020, and by late 2023 a CRISPR product had full regulatory approval. But the gap between “first approval for a rare disease” and “widely available for common conditions” will be measured in years, not months.